DK1451177T3 - Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne - Google Patents

Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne

Info

Publication number
DK1451177T3
DK1451177T3 DK02798318T DK02798318T DK1451177T3 DK 1451177 T3 DK1451177 T3 DK 1451177T3 DK 02798318 T DK02798318 T DK 02798318T DK 02798318 T DK02798318 T DK 02798318T DK 1451177 T3 DK1451177 T3 DK 1451177T3
Authority
DK
Denmark
Prior art keywords
migraine
pyrrolidin
substituted
treatment
indole derivatives
Prior art date
Application number
DK02798318T
Other languages
English (en)
Inventor
Corinna Sundermann
Bernd Sundermann
Helmut Buschmann
Hagen-Heinrich Hennies
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1451177T3 publication Critical patent/DK1451177T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
DK02798318T 2001-12-06 2002-12-02 Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne DK1451177T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159922A DE10159922A1 (de) 2001-12-06 2001-12-06 Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
PCT/EP2002/013613 WO2003048156A1 (de) 2001-12-06 2002-12-02 Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne

Publications (1)

Publication Number Publication Date
DK1451177T3 true DK1451177T3 (da) 2007-07-02

Family

ID=7708242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02798318T DK1451177T3 (da) 2001-12-06 2002-12-02 Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne

Country Status (18)

Country Link
US (1) US7271192B2 (da)
EP (1) EP1451177B1 (da)
JP (1) JP4663982B2 (da)
AR (1) AR037707A1 (da)
AT (1) ATE357441T1 (da)
AU (1) AU2002363859B2 (da)
CA (1) CA2469346C (da)
CY (1) CY1106576T1 (da)
DE (2) DE10159922A1 (da)
DK (1) DK1451177T3 (da)
ES (1) ES2284973T3 (da)
HU (1) HUP0402283A3 (da)
MX (1) MXPA04005139A (da)
PE (1) PE20030748A1 (da)
PL (1) PL371270A1 (da)
PT (1) PT1451177E (da)
SI (1) SI1451177T1 (da)
WO (1) WO2003048156A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006132275A1 (ja) 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および/または治療剤
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CN112010841A (zh) * 2020-08-20 2020-12-01 上海体育学院 一种基于吲哚骨架的吡咯烷衍生物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3506683A (en) * 1963-10-07 1970-04-14 Upjohn Co 3-(2-pyrrolidinylidene)-3h-indoles
CA2124206C (en) * 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
GB9523999D0 (en) * 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
US20030055037A1 (en) * 2000-10-06 2003-03-20 Delombaert Stephane Benzimidazole and indole derivatives as CRF receptor modulators

Also Published As

Publication number Publication date
CA2469346C (en) 2010-10-19
ATE357441T1 (de) 2007-04-15
US7271192B2 (en) 2007-09-18
EP1451177B1 (de) 2007-03-21
WO2003048156A1 (de) 2003-06-12
PT1451177E (pt) 2007-04-30
JP2005511694A (ja) 2005-04-28
MXPA04005139A (es) 2004-08-11
DE50209798D1 (de) 2007-05-03
PE20030748A1 (es) 2003-09-05
CY1106576T1 (el) 2012-01-25
AU2002363859A1 (en) 2003-06-17
AU2002363859B2 (en) 2008-09-18
ES2284973T3 (es) 2007-11-16
SI1451177T1 (sl) 2007-08-31
HUP0402283A2 (hu) 2005-02-28
CA2469346A1 (en) 2003-06-12
PL371270A1 (en) 2005-06-13
US20050014815A1 (en) 2005-01-20
EP1451177A1 (de) 2004-09-01
DE10159922A1 (de) 2003-06-26
HUP0402283A3 (en) 2009-07-28
AR037707A1 (es) 2004-12-01
JP4663982B2 (ja) 2011-04-06

Similar Documents

Publication Publication Date Title
DK1762567T3 (da) Pyrazolderivater til behandling af HIV
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1438306T3 (da) Derivater af UK-2A
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
IL229160B (en) Rapamycin derivatives for treatment of solid tumors
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
NO20040253L (no) Fremgangsmater for behandling av leverfibroser
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1667967T3 (da) Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater